Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
← catalyst calendarSponsored by Precigen, Inc (industry) · PGEN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
71estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-30 | actual | When the study began enrolling |
| Primary completion | 2024-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2019-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Fallopian Tube Carcinoma
- Refractory Ovarian Carcinoma
- Refractory Primary Peritoneal Carcinoma
- Stage III Fallopian Tube Cancer AJCC V8
- Stage III Ovarian Cancer AJCC V8
- Stage III Primary Peritoneal Cancer AJCC V8
- Stage IIIA Fallopian Tube Cancer AJCC V8
- Stage IIIA Ovarian Cancer AJCC V8
- Stage IIIA Primary Peritoneal Cancer AJCC V8
- Stage IIIA1 Fallopian Tube Cancer AJCC V8
- Stage IIIA1 Ovarian Cancer AJCC V8
- Stage IIIA2 Fallopian Tube Cancer AJCC V8
- Stage IIIA2 Ovarian Cancer AJCC V8
- Stage IIIB Fallopian Tube Cancer AJCC V8
- Stage IIIB Ovarian Cancer AJCC V8
- Stage IIIB Primary Peritoneal Cancer AJCC V8
- Stage IIIC Fallopian Tube Cancer AJCC V8
- Stage IIIC Ovarian Cancer AJCC V8
- Stage IIIC Primary Peritoneal Cancer AJCC V8
- Stage IV Fallopian Tube Cancer AJCC V8
- Stage IV Ovarian Cancer AJCC V8
- Stage IV Primary Peritoneal Cancer AJCC V8
- Stage IVA Fallopian Tube Cancer AJCC V8
- Stage IVA Ovarian Cancer AJCC V8
- Stage IVA Primary Peritoneal Cancer AJCC V8
- Stage IVB Fallopian Tube Cancer AJCC V8
- Stage IVB Ovarian Cancer AJCC V8
- Stage IVB Primary Peritoneal Cancer AJCC V8
Interventions
- Biological: PRGN-3005 UltraCAR-T cells
- Biological: PRGN-3005 UltraCAR-T cells
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events
measured Up to 12 months after infusion
Maximal tolerated dose of PRGN-3005
measured Up to 28 days
Permalink · PGEN's whole pipeline · Catalyst calendar · Every registered study · What changed